본문 바로가기
KERD
논문KCI 등재

Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?

배치운|Won-Myong Bahk|Changsu Han|Soo-Jung Lee|Ashwin A. Patkar|Prakash S. Masand
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2021.08|Clinical Psychopharmacology and Neuroscience|제19권 제3호|pp. 434-448|DOI 10.9758/cpn.2021.19.3.434

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

GuidelineSchizophreniaMonotherapyPolypharmacyLong-acting injectable antipsychoticRoutine practice.

초록

Antipsychotic monotherapy (APM) is considered best-acceptable treatment option regardless of antipsychotic class and formulation types for treating schizophrenia. However, antipsychotic polypharmacy (APP) has been also widely utilized in routine clinical practice. Despite APP has some clinical benefits it has also numerous pitfalls in relation with increased total number and doses of APs leading to adverse events as well as decrease of treatment adherence and persistence resulting in poor clinical outcomes. Recent introduction of long-acting injectable antipsychotics (LAIs) to the market has offered a chance for better medication adherence/persistence and also provided a simplification of treatment regime leading to more stabilized treatment for schizophrenia patients. When we cannot stay away from APP in the treatment of schizophrenia, clinicians need to find more proper APP regimens and thereby utilization of APP in efficient way should be a practical strategy to benefit schizophrenia patient in a real world treatment setting. With this regard, LAIs can be one of available APP regimen for treatment of schizophrenia in routine practice since their clinical utility and pharmacokinetic stability over oral APs have been well-elaborated today. However, when we have to commence LAIs as a part of APP with oral APs or other LAIs, every effort should be made before doing so whether or not validated and available treatment options or other clinical factors were not done or evaluated yet. Any treatment guidelines do not support APP regardless of the formulation of APP regimen or address two or more LAIs for treatment of schizophrenia till today.

Abstract

Antipsychotic monotherapy (APM) is considered best-acceptable treatment option regardless of antipsychotic class and formulation types for treating schizophrenia. However, antipsychotic polypharmacy (APP) has been also widely utilized in routine clinical practice. Despite APP has some clinical benefits it has also numerous pitfalls in relation with increased total number and doses of APs leading to adverse events as well as decrease of treatment adherence and persistence resulting in poor clinical outcomes. Recent introduction of long-acting injectable antipsychotics (LAIs) to the market has offered a chance for better medication adherence/persistence and also provided a simplification of treatment regime leading to more stabilized treatment for schizophrenia patients. When we cannot stay away from APP in the treatment of schizophrenia, clinicians need to find more proper APP regimens and thereby utilization of APP in efficient way should be a practical strategy to benefit schizophrenia patient in a real world treatment setting. With this regard, LAIs can be one of available APP regimen for treatment of schizophrenia in routine practice since their clinical utility and pharmacokinetic stability over oral APs have been well-elaborated today. However, when we have to commence LAIs as a part of APP with oral APs or other LAIs, every effort should be made before doing so whether or not validated and available treatment options or other clinical factors were not done or evaluated yet. Any treatment guidelines do not support APP regardless of the formulation of APP regimen or address two or more LAIs for treatment of schizophrenia till today.

참고문헌 (97)

  1. Konstantinos N. Fountoulakis, "One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study", Clinical Psychopharmacology and Neuroscience, 18(3), pp.434~444 (2020), 대한정신약물학회[DOI]
  2. Katona L, "Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia:to switch or to combine? A nationwide study in Hungary", Schizophr Res, 152, pp.246~254 (2014)
  3. Jeong Ha Park, "Effects of Amisulpride Adjunctive Therapy on Working Memory and Brain Metabolism in the Frontal Cortex of Patients with Schizophrenia: A Preliminary Positron Emission Tomography", Computerized Tomography Investigation, 2019, pp.17(2), 250~260[DOI]
  4. Jung Suk Lee, "Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms", Clinical Psychopharmacology and Neuroscience, 18(3), pp.386~394 (2020), 대한정신약물학회[DOI]
  5. José Andrés Espejo Oltra, "Improving Therapeutic Interventions of Schizophrenia with Advances in Stem Cell Technology", Clinical Psychopharmacology and Neuroscience, 18(3), pp.352~361 (2020), 대한정신약물학회[DOI]
  6. Dong M, "Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients : findings of the 2016 Research on Asian Psychotropic Prescription Patterns(REAP)survey", Asian J Psychiatr, 45, pp.74~80 (2019)
  7. Hasan A, "World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance", World J Biol Psychiatry, 13, pp.318~378 (2012)
  8. Barnes TR, "Evidence-based guidelines for the pharmacological treatment of schizophrenia : updated recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 34, pp.3~78 (2020)
  9. Galletly C, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders", Aust N Z J Psychiatry, 50, pp.410~472 (2016)
  10. Lehman AF, "Practice guideline for the treatment of patients with schizophrenia, second edition", Am J Psychiatry, 161(2 Suppl), pp.1~56 (2004)
  11. Remington G, "Guidelines for the pharmacotherapy of schizophrenia in adults", Can J Psychiatry, 62, pp.604~616 (2017)
  12. Stahl SM, "Emerging guidelines for the use of antipsychotic polypharmacy", Rev Psiquiatr Salud Ment, 6, pp.97~100 (2013)
  13. Keepers GA, "The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia", Am J Psychiatry, 177, pp.868~872 (2020)
  14. "Psychosis and schizophrenia in adults: prevention and management" (2014)[URL]
  15. Hatta K, "Real-world effectiveness of antipsychotic monotherapy and polytherapy in 1543 patients with acute-phase schizophrenia", Asian J Psychiatr, 40, pp.82~87 (2019)
  16. Guinart D, "Antipsychotic polypharmacy in schizophrenia: why not?", J Clin Psychiatry, 81, pp.19~ (2020)
  17. Sun F, "Polypharmacy with antipsychotic drugs in patients with schizophrenia : trends in multiple health care systems", Am J Health Syst Pharm, 71, pp.728~738 (2014)
  18. Galling B, "Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and metaregression analysis", World Psychiatry, 16, pp.77~89 (2017)
  19. Tiihonen J, "Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia", JAMA Psychiatry, 76, pp.499~507 (2019)
  20. Roh D, "Antipsychotic polypharmacy and high-dose prescription in schizophrenia : a 5-year comparison", Aust N Z J Psychiatry, 48, pp.52~60 (2014)
  21. Aly El-Gabry DM, "Antipsychotic polypharmacy and its relation to metabolic syndrome in patients with schizophrenia : an Egyptian study", J Clin Psychopharmacol, 38, pp.27~33 (2018)
  22. Takeuchi H, "Antipsychotic polypharmacy and corrected QT interval : a systematic review", Can J Psychiatry, 60, pp.215~222 (2015)
  23. Jhin Goo Chang, "Association between Therapeutic Alliance and Adherence in Outpatient Schizophrenia Patients", Clinical Psychopharmacology and Neuroscience, 17(2), pp.273~278 (2019), 대한정신약물학회[DOI]
  24. Yujin Lee, "Medication Adherence Using Electronic Monitoring in Severe Psychiatric Illness: 4 and 24 Weeks after Discharge", Clinical Psychopharmacology and Neuroscience, 17(2), pp.288~296 (2019), 대한정신약물학회[DOI]
  25. 배치운, "Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and", or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study, 2020, pp.18(1), 153~158[DOI]
  26. Hiroyuki Kamei, "Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia", Clinical Psychopharmacology and Neuroscience, 18(1), pp.49~57 (2020), 대한정신약물학회[DOI]
  27. Dasom Lee, "Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea", Clinical Psychopharmacology and Neuroscience, 18(2), pp.303~310 (2020), 대한정신약물학회[DOI]
  28. Wang SM, "Schizophrenia relapse and the clinical usefulness of oncemonthly aripiprazole depot injection", Neuropsychiatr Dis Treat, 10, pp.1605~1611 (2014)
  29. Gallego JA, "Prevalence and correlates of antipsychotic polypharmacy : a systematic review and meta-regression of global and regional trends from the 1970s to 2009", Schizophr Res, 138, pp.18~28 (2012)
  30. Correll CU, "Antipsychotic polypharmacy : a comprehensive evaluation of relevant correlates of a long-standing clinical practice", Psychiatr Clin North Am, 35, pp.661~681 (2012)
  31. Dimitropoulos E, "Evaluation of concurrent oral and long-acting injectable antipsychotic prescribing at the Minneapolis veterans affairs health care system", J Clin Psychopharmacol, 37, pp.605~608 (2017)
  32. Doshi JA, "Concurrent oral antipsychotic drug use among schizophrenia patients initiated on long-acting injectable antipsychotics post-hospital discharge", J Clin Psychopharmacol, 35, pp.442~446 (2015)
  33. Constantine RJ, "Is the risk of antipsychotic polypharmacy discontinuation dependent on the agents used?", Psychiatry Res, 263, pp.238~244 (2018)
  34. Marcus SC, "Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge", J Manag Care Spec Pharm, 21, pp.754~768 (2015)
  35. Hodgson RE, "Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting", Clinicoecon Outcomes Res, 11, pp.517~524 (2019)
  36. Iwata N, "Treatment persistence between long-acting injectable versus orally administered aripiprazole among patients with schizophrenia in a real-world clinical setting in Japan", Adv Ther, 37, pp.3324~3336 (2020)
  37. Mahlich J, "Hospitalization rates and therapy costs of German schizophrenia patients who are initiated on long-acting injectable medication : a mirror-image study", Clin Drug Investig, 40, pp.355~375 (2020)
  38. Lin CH, "Time to rehospitalization in patients with schizophrenia receiving long-acting injectable antipsychotics or oral antipsychotics", Int J Neuropsychopharmacol, 22, pp.541~547 (2019)
  39. Kishimoto T, "Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia : a meta-analysis of randomized trials", Schizophr Bull, 40, pp.192~213 (2014)
  40. Kane JM, "Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry", J Clin Epidemiol, 66(8 Suppl), pp.S37~S41 (2013)
  41. Tani H, "Factors associated with successful antipsychotic dose reduction in schizophrenia : a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials", Neuropsychopharmacology, 45, pp.887~901 (2020)
  42. Graff-Guerrero A, "Evaluation of antipsychotic dose reduction in late-life schizophrenia : a prospective dopamine D2", 3 receptor occupancy study, 2015, pp.72, 927~934
  43. Uchida H, "Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia : meta-analysis", Schizophr Bull, 37, pp.788~799 (2011)
  44. McCutcheon R, "Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms", J Psychopharmacol, 29, pp.892~897 (2015)
  45. Lopez LV, "Accuracy of clinician assessments of medication status in the emergency setting : a comparison of clinician assessment of antipsychotic usage and plasma level determination", J Clin Psychopharmacol, 37, pp.310~314 (2017)
  46. Sheehan JJ, "Comparison of the peakto-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents", Innov Clin Neurosci, 9, pp.17~23 (2012)
  47. Bai YM, "Equivalent switching dose from oral risperidone to risperidone long-acting injection : a 48-week randomized, prospective, single-blind pharmacokinetic study", J Clin Psychiatry, 68, pp.1218~1225 (2007)
  48. Ereshefsky L, "Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics", J Clin Psychiatry, 64(Suppl 16), pp.18~23 (2003)
  49. Eerdekens M, "Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia", Schizophr Res, 70, pp.91~100 (2004)
  50. Mannaert E, "Pharmacokinetic profile of long-acting injectable risperidone at steady-state : comparison with oral administration", Encephale, 31(5 Pt 1), pp.609~615 (2005)
  51. Raoufinia A, "Initiation of aripiprazole once-monthly in patients with schizophrenia", Curr Med Res Opin, 31, pp.583~592 (2015)
  52. Hard ML, "Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil : a phase I study and a population pharmacokinetic model", CNS Drugs, 31, pp.617~624 (2017)
  53. Hard ML, "Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil", Eur J Drug Metab Pharmacokinet, 43, pp.461~469 (2018)
  54. Jann MW, "Clinical pharmacokinetics of the depot antipsychotics", Clin Pharmacokinet, 10, pp.315~333 (1985)
  55. Cruz MP, "Aripiprazole lauroxil(Aristada) : an extended-release, long-acting injection for the treatment of schizophrenia", P T, 41, pp.556~559 (2016)
  56. Di Lorenzo R, "Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia", Neuropsychiatr Dis Treat, 6, pp.573~581 (2010)
  57. Di Lorenzo R, "Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia : retrospective study in a real-world clinical setting", Neuropsychiatr Dis Treat, 15, pp.183~198 (2019)
  58. García-Carmona JA, "Long-acting injectable antipsychotics : analysis of prescription patterns and patient characteristics in mental health from a Spanish real-world study", Clin Drug Investig, 40, pp.459~468 (2020)
  59. Pae CU, "Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia : systematic review and indirect treatment comparison", Int Clin Psychopharmacol, 32, pp.235~248 (2017)
  60. Park MH, "Aripiprazole treatment for patients with schizophrenia : from acute treatment to maintenance treatment", Expert Rev Neurother, 11, pp.1541~1552 (2011)
  61. Kane JM, "Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia : a 52-week, multicenter, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 73, pp.617~624 (2012)
  62. Fleischhacker WW, "Aripiprazole once-monthly for treatment of schizophrenia : double-blind, randomised, noninferiority study", Br J Psychiatry, 205, pp.135~144 (2014)
  63. Kane JM, "Aripiprazole once-monthly in the acute treatment of schizophrenia : findings from a 12-week, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 75, pp.1254~1260 (2014)
  64. Kane JM, "Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly : final efficacy analysis", J Med Econ, 18, pp.145~154 (2015)
  65. Kane JM, "Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia : a randomized clinical trial", JAMA Psychiatry, 77, pp.1~8 (2020)
  66. Naber D, "Qualify : a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia", Schizophr Res, 168, pp.498~504 (2015)
  67. Potkin SG, "Multidimensional assessment of functional outcomes in schizophrenia : results from QUALIFY, a head-tohead trial of aripiprazole once-monthly and paliperidone palmitate", Int J Neuropsychopharmacol, 20, pp.40~49 (2017)
  68. Potkin SG, "Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate : results from QUALIFY", Int Clin Psychopharmacol, 32, pp.147~154 (2017)
  69. Potkin SG, "Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia : a post-hoc analysis of the QUALIFY study", PLoS One, 12, pp.e0183475~ (2017)
  70. Naber D, "Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study", Schizophr Res, 192, pp.205~210 (2018)
  71. Shapiro DA, "Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology", Neuropsychopharmacology, 28, pp.1400~1411 (2003)
  72. Suzuki H, "Comparisons of the effects of second-generation antipsychotics long-acting injections on treatment retention according to severity of patient condition", Asian J Psychiatr, 37, pp.64~66 (2018)
  73. Cuomo I, "Head-to-head comparison of 1-year aripiprazole long-acting injectable(LAI)versus paliperidone LAI in comorbid psychosis and substance use disorder : impact on clinical status, substance craving, and quality of life", Neuropsychiatr Dis Treat, 14, pp.1645~1656 (2018)
  74. Brown ES, "Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole", J Clin Psychiatry, 66, pp.756~760 (2005)
  75. Feltenstein MW, "Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse", Biol Psychiatry, 61, pp.582~590 (2007)
  76. Balcioglu YH, "One plus one sometimes equals more than two : long-acting injectable aripiprazole adjunction in clozapine-resistant schizophrenia", Clin Neuropharmacol, 43, pp.166~168 (2020)
  77. Lindenmayer JP, "Long-acting injectable antipsychotics : focus on olanzapine pamoate", Neuropsychiatr Dis Treat, 6, pp.261~267 (2010)
  78. Detke HC, "Post-injection delirium", sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I : analysis of cases, 2010, pp.10, 43~
  79. Anand E, "Clinical outcomes with olanzapine long-acting injection : impact of the 3-hour observation period on patient satisfaction and wellbeing", Neuropsychiatr Dis Treat, 12, pp.2737~2743 (2016)
  80. Martel ML, "A large retrospective cohort of patients receiving intravenous olanzapine in the emergency department", Acad Emerg Med, 23, pp.29~35 (2016)
  81. Kishi T, "Intramuscular olanzapine for agitated patients : a systematic review and meta-analysis of randomized controlled trials", J Psychiatr Res, 68, pp.198~209 (2015)
  82. Rainer MK, "Risperidone long-acting injection : a review of its long term safety and efficacy", Neuropsychiatr Dis Treat, 4, pp.919~927 (2008)
  83. Emsley R, "Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis : a preliminary study", J Clin Psychopharmacol, 28, pp.210~213 (2008)
  84. Weiden PJ, "A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients : initial adherence outcome", J Clin Psychiatry, 70, pp.1397~1406 (2009)
  85. Jann MW, "Long-acting injectable second-generation antipsychotics : an update and comparison between agents", CNS Drugs, 32, pp.241~257 (2018)
  86. Wartelsteiner F, "Treating schizophrenia with 2 longacting injectable antipsychotic drugs : a case report", J Clin Psychopharmacol, 35, pp.474~475 (2015)
  87. Ross C, "High dose haloperidol decanoate augmentation with paliperidone palmitate", College of Psychiatric and Neurologic Pharmacists 16th Annual Meeting (2013)
  88. McInnis P, "Combination long-acting injectable(LAI)antipsychotic medication in adolescents with severe psychosis and aggression : a case series", Australas Psychiatry, 27, pp.160~164 (2019)
  89. Ladds B, "Concurrent use of two depot antipsychotic medications in schizophrenia", Internet J Psychiatry, 1, pp.1~ (2009)
  90. Scangos KW, "Multiple long-acting injectable antipsychotics for treatment-resistant schizophrenia : case report", J Clin Psychopharmacol, 36, pp.283~285 (2016)
  91. Diefenderfer LA, "When should you consider combining 2long-acting injectable antipsychotics?", Curr Psychiatry, 16, pp.42~46 (2017)
  92. Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
  93. "Encephale", 2018, 496~503
  94. Citrome L, "Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States", J Med Econ, 17, pp.567~576 (2014)
  95. Sapin C, "Corrigendum : Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia : a US analysis", Drugs Context, 6, pp.212504~ (2017)
  96. Druais S, "Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France", Pharmacoeconomics, 34, pp.363~391 (2016)
  97. Suzuki H, "Comparisons of the effects of long-acting injectable monotherapy and combination therapy of long-acting injectable treatment with oral antipsychotics on treatment retention in patients with chronic schizophrenia", Asian J Psychiatr, 39, pp.112~113 (2019)

관련 논문AI추천

Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia배치운, Ashwin A. Patkar, Changsu Han, Jung-Jin Kim, Prakash S. Masand, Soo-Jung Lee, Won-Myong Bahk대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2021 · 제19권 제4호The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release강민희, 김철응, 김희윤, 나경세, 배재남, 이정섭, 이희원, 정승호대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2013 · 제11권 제3호Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study박원명, 배치운, 이수정, Ashwin A Patkar, Changsu Han, Prakash S Masand대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2020 · 제18권 제1호Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation StudyAshwin A Patkar, Changsu Han, Chi-Un Pae, Prakash S. Masand, Soo-Jung Lee, Won-Myong Bahk대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2021 · 제19권 제2호Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case SeriesHanae Yamada, Hiroyuki Kamei, Manako Hanya, Masakazu Hatano, Nakao Iwata, Shigeki Yamada대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2020 · 제18권 제1호장기지속형 항정신병약물의 임상 실제이규영대한신경정신의학회 · 신경정신의학2019 · 제58권 제1호

이 간행물의 다른 논문 (19건)

A New Look on an Old Issue: Comprehensive Review of Neurotransmitter Studies in Cerebrospinal Fluid of Patients with Schizophrenia and Antipsychotic Effect on Monoamine’s MetabolismMarion Plaze, Pierre Abdel Ahad, Matthieu Gasnier, Pierre Ellulpp. 395-410Challenges in Prescribing Clozapine in the Era of COVID-19: A Review Focused on Immunological ImplicationsSeong Hoon Jeong, Yong Sik Kimpp. 411-422Novel Biomarkers of Alzheimer’s Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative StressYi-Hsiang Yu, Ting-I Chiang, Hsien-Yuan Lane, Chieh-Hsin Linpp. 423-433White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive DisorderMin-Soo Kwon, Hoyoung Sohn, Jaehwa Lim, 김보라pp. 449-458Real-world Evaluation of Tolerability, Safety and Efficacy of Rivastigmine Oral Solution in Patients with Mild to Moderate Alzheimer’s Disease DementiaKai-Ming Jhang, Wenfu Wang, Yuan-Han Yang, Sun-Wung Hsieh, Jui-Cheng Chen, Nai-Ching Chenpp. 459-469
원문 보기